Table 3 Qualitative and quantitative clinical characteristics of the dogs depending on the preventive measures used

NON (N = 318)

50 (44.4–55.6)

50 (44.4–55.6)

69.1 (63.7–74.1)

30.9 (25.9–36.3)

7.1 (± 3.5)

20 (± 14.3)

71.9 (66.6–76.8)

28.1 (23.2–33.4)

REP (N = 1468)

55.9 (53.3–58.5)

44.1 (41.5–46.7)

71.8 (69.4–74.1)

28.2 (25.9–30.6)

7 (± 3.4)

18.8 (± 13.2)

66.4 (63.9–68.8)

33.6 (31.2–36.1)

CAN (N = 125)

52 (42.9–61)

48 (39–57.1)

75 (66.4–82.3)

25 (17.7–33.6)

6.5 (± 2.8)

21.8 (± 14.6)

69.4 (60.4–77.3)

30.6 (22.7–39.6)

LET (N = 28)

53.6 (33.9–72.5)

46.4 (27.5–66.1)

71.4 (51.3–86.8)

28.6 (13.2–48.7)

4.4 (± 3.7)

19 (± 10.1)

60.7 (40.6–78.5)

39.3 (21.5–59.4)

LEI (N = 39)

41 (25.6–57.9)

59 (42.1–74.4)

61.5 (44.6–76.6)

38.5 (23.4–55.4)

8.8 (± 3.3)

11.9 (± 14.1)

43.6 (27.8–60.4)

56.4 (39.6–72.2)

CAN + REP (N = 719)

53.8 (50.1–57.5)

46.2 (42.5–49.9)

77 (73.7–80)

23 (20–26.3)

6.3 (± 3.1)

18 (± 14.7)

72.4 (69–75.6)

27.6 (24.4–31)

LET + REP (N = 527)

51.4 (47.1–55.8)

48.6 (44.2–52.9)

71.9 (67.9–75.7)

28.1 (24.3–32.1)

5.8 (± 3.3)

19 (± 13.1)

89.9 (87.1–92.4)

10.1 (7.6–13)

LEI + REP (N = 436)

52.5 (47.7–57.3)

47.5 (42.7–52.3)

70 (65.5–74.3)

30 (25.7–34.5)

6.1 (± 3.2)

12 (± 13.5)

53.8 (49–58.6)

46.2 (41.4–51)

CAN + LEI (N = 9)

22.2 (2.8–60)

77.8 (40–97.2)

44.4 (13.7–78.8)

55.6 (21.2–86.3)

4.4 (± 3.5)

10 (± 13.2)

88.9 (51.8–99.7)

11.1 (0–48.3)

CAN + LEI + REP (N = 57)

41.4 (28.6–55.1)

58.6 (44.9–71.4)

75 (61.6–85.6)

25 (14.4–38.4)

6 (± 3)

17.8 (± 15.7)

71.9 (58.5–83)

28.1 (17–41.5)

LET + LEI + REP (N = 32)

53.1 (34.7–70.9)

46.9 (29.1–65.3)

68.8 (50–83.9)

31.2 (16.1–50)

6 (± 1.2)

22.5 (± 16.8)

78.1 (60–90.7)

21.9 (9.3–40)

P-value

P < 0.0001*^a

P < 0.0001*^b

P < 0.0001*^c

P < 0.0001*^d

P < 0.0001*^e